Skip to Content
  1. All products
  2. Recovery & Regeneration
  3. GLOW (GHK-CU/TB-500/BPC-157)
  4. Recovery & Regeneration
Pricelist: Default Pricelist Pricelist
Pricelist: Default Pricelist Pricelist
GLOW (GHK-CU/TB-500/BPC-157)

GLOW (GHK-CU/TB-500/BPC-157)

Blend · Subcutaneous, Topical, Intradermal Refrigerate after reconstitution (2-8°C). Discard after 60 days or if contaminated. 99% Purity · USP Grade
99% Purity
PHYSICIAN USE ONLY
$ 132.00 $ 132.00

Format
⚗ blend
  • Strength
Add to cart
Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days
Clinical Description

Tissue repair, collagen synthesis, improved skin tone, hair growth, faster wound healing, cosmetic recovery

El Glow Blend combina BPC-157, TB-500 y GHK-CU para una recuperación regenerativa y cosmética que promueve la reparación de tejidos, la síntesis de colágeno, un mejor tono de la piel, el crecimiento del cabello y una curación más rápida de las heridas.

Clinical Indications
Post-procedure recovery protocolsConnective tissue and skin repair supportInflammation and healing pathway support
Recommended Stacking Protocols
✓
CJC-1295 + Ipamorelin
Boosts endogenous GH release → enhanced collagen and repair
✓
Epithalon
Cellular longevity & telomere support
✓
Thymosin Alpha-1
Immune optimization during healing
Blend Components
Component Amount (mg)
BPC-157 10
TB-500 10
GHK-Cu 50

Mechanism of Action - Recovery & Tissue Repair Pathway

Targeted Signaling
Supports protocol objectives for GLOW (GHK-CU/TB-500/BPC-157).
Clinical Modulation
Allows dose and schedule adjustments by response.
Outcome Tracking
Pairs with clinician monitoring for iterative optimization.
Starting Dose
Low initial dose
Initiation phase for tolerance and baseline response.
Titration
Escalate by protocol
Maintenance Range
Maintain physician-directed target
Adjust based on objective outcomes and physician review.
Suggested Dosing Notes

Frecuencia:1× al día para antienvejecimiento;2 veces al día para la reparación de tejidos.

Ciclo:6-10 semanas (Mezcla 1) u 8-12 semanas (Mezcla 2)

Sitios de inyección:SubQ al abdomen o área localizada de lesión

Period Dose Phase Clinical Notes
Weeks 1-2 Initial phase initiation Begin conservatively and monitor tolerance.
Weeks 3-6 Escalation phase escalation Increase per protocol if tolerated.
Week 7+ Maintenance phase maintenance Maintain target dose and reassess monthly.
Preparation Protocol
  1. Inyecte con el estómago vacío cuando sea posible para mejorar la biodisponibilidad.
  2. Vía: Inyección subcutánea o intradérmica.
  3. Refrigerar después de la reconstitución (2-8°C). Deseche después de 60 días o si está contaminado.
1
Inspect vial
Confirm vial integrity, lot, and expiration before use.
2
Aseptic reconstitution
Disinfect stopper and add bacteriostatic water slowly.
3
Gentle dissolution
Swirl gently until the solution is clear and homogeneous.
4
Prepare dose
Draw dose according to reconstitution conversion guidance.
Reconstitution & Dosing Guide
Standard 1 mL insulin syringe: 100 units = 1 mL

Total Peptide: 70 mg
BW: 3 mL
Concentration: 23.33mg/mL total (BPC-157=3.33mg/mL, TB-500=3.33mg/mL, GHK-Cu=16.67mg/mL)
Dose Units to Draw Volume (mL) Approx. Supply
250mcg BPC + 250mcg TB + 1mg GHK-Cu 6 units - 50 doses
500mcg BPC + 500mcg TB + 2mg GHK-Cu 12 units - 25 doses

Total Peptide: 90 mg
BW: 5 mL
Concentration: 16mg/mL total (BPC-157=2mg/mL, TB-500=2mg/mL, GHK-Cu=14mg/mL)
Dose Units to Draw Volume (mL) Approx. Supply
250mcg BPC + 250mcg TB + 1mg GHK-Cu 9 units - 55 doses
500mcg BPC + 500mcg TB + 2mg GHK-Cu 18 units - 28 doses
Identity
  • Product Name: GLOW (GHK-CU/TB-500/BPC-157)
  • Product Type: Blend | Subcutaneous or Intradermal Injection
  • Strength Options: 50/10/10 mg
  • Components: BPC-157 + TB-500 + GHK-Cu
  • Available Blends: Blend 1: 10mg/10mg/50mg, Blend 2: 10mg/10mg/70mg
Quality & Purity
  • Purity: >= 99%
  • Sterility: Aseptic handling required
  • Purity: 99%+
Storage & Handling
  • Storage: 2-8 C refrigerated
  • Handling: Avoid heat, shaking, and direct light
  • Storage: Refrigerate after reconstitution (2-8°C). Discard after 60 days.

Timing: Use consistent administration timing for stable protocol tracking.

Storage: Refrigerate after reconstitution (2-8°C). Discard after 60 days or if contaminated.

Frequency: Frequency:1xdaily for anti-aging:2xdaily for tissue repair. ·Frequency:1xdailyformaintenance;2xdailyfor active healingorpost-procedurerecovery.

Cycle: .Cycle:6-10weeks. Cycle:8-12weeks(extendableforlong-termskin/tendonsupport).

Injection Sites: Route-Subcutaneous orintradermal injection(can also be diluted for topical use). Injection Sites:SubQ to abdomen or localized area of injury (or micro-inject face/neckfor cosmetic use). InjectionSites:SubQ abdomen or target injuryarea;intradermalmicro-dose for skin applications.